-
公开(公告)号：EP2928886A1
公开(公告)日：2015-10-14
申请号：EP13802010.2
申请日：2013-12-02
IPC分类号： C07D403/12 , C07D401/12 , C07D405/12 , C07D407/12 , C07D413/12 , C07D419/12 , C07D307/80 , A61K31/352 , A61K31/404 , A61K31/4155 , A61K31/4178 , A61K31/423 , A61K31/426 , A61P3/10
CPC分类号： A61K31/343 , A61K31/085 , A61K31/09 , A61K31/192 , A61K31/34 , A61K31/351 , A61K31/357 , A61K31/36 , A61K31/4025 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/416 , A61K31/4178 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/443 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D307/80 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to compounds of general formula I, wherein the groups (Het)Ar and R
1 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.摘要翻译： 本发明涉及通式I的化合物，其中基团（Het）Ar和R 1如权利要求1中所定义，其具有有价值的药理学性质，特别是与GPR40受体结合并调节其活性。 该化合物适用于治疗和预防可受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
-
2.发明授权Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome 有权对于代谢综合征合适Indanyloxydihydrobenzofuranylessigsäuren的治疗
公开(公告)号：EP2646425B1
公开(公告)日：2015-06-10
申请号：EP11788845.3
申请日：2011-11-30
发明人： HIMMELSBACH, Frank , BAKKER, Remko , ECKHARDT, Matthias , HAMPRECHT, Dieter , LANGKOPF, Elke , WAGNER, Holger
IPC分类号： C07D307/80 , C07D405/12 , C07D407/12 , C07D413/12 , A61K31/343 , A61P3/10
CPC分类号： C07D307/80 , C07D405/12 , C07D407/12 , C07D413/12
-
3.发明授权
公开(公告)号：EP2331506B1
公开(公告)日：2013-07-03
申请号：EP09782238.1
申请日：2009-08-26
IPC分类号： C07D213/89 , C07D213/68 , C07D239/34 , C07D239/47 , C07D401/12 , C07D403/04 , C07D403/06 , C07D405/12 , C07D401/06 , C07D403/12 , A61P11/00 , A61K31/505 , A61K31/444 , A61K31/4433 , A61K31/443 , A61K31/4439 , C07D213/74 , C07D239/46
CPC分类号： C07D403/04 , C07D213/68 , C07D213/74 , C07D213/89 , C07D239/34 , C07D239/42 , C07D239/46 , C07D401/04 , C07D401/06 , C07D401/12
-
4.发明公开7-(PIPERAZIN-1-YLMETHYL)-1H-INDOL-2-CARBONSÄURE (PHENYL) -AMIDDERIVATE UND VERWANDTE VERBINDUNGEN ALS P38 MAP-KINASE-INHIBITOREN ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN 有权7-（哌嗪-1-基甲基）-1H-吲哚-2-羧酸（苯基）-AMIDDERIVATE及相关化合物AS p38 MAP激酶抑制剂呼吸系统疾病的治疗
公开(公告)号：EP2323980A1
公开(公告)日：2011-05-25
申请号：EP09782239.9
申请日：2009-08-26
IPC分类号： C07D209/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , A61K31/404 , A61P11/00
CPC分类号： C07D209/42
摘要： The invention relates to compounds of general formula (I) for the treatment of respiratory diseases, in particular asthma and COPD.
-
5.发明公开SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS 审中-公开取代的芳基磺酰氨基亚甲基膦酸衍生物及其制备和它们在治疗I型和II型糖尿病中的用途
公开(公告)号：EP2185571A1
公开(公告)日：2010-05-19
申请号：EP08786464.1
申请日：2008-07-25
发明人： WAGNER, Holger , LANGKOPF, Elke , ECKHARDT, Matthias , STREICHER, Ruediger , SCHOELCH, Corinna , SCHULER-METZ, Annette , PAUTSCH, Alexander
IPC分类号： C07F9/572 , C07F9/6503 , C07F9/6506 , C07F9/653 , C07F9/6541 , C07F9/6553 , C07F9/6558 , A61K31/67 , A61K31/675 , A61P3/10
CPC分类号： C07F9/5728 , C07F9/65038 , C07F9/65068 , C07F9/65324 , C07F9/6541 , C07F9/655354 , C07F9/65583 , C07F9/65586
摘要： The present invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.
摘要翻译： 本发明涉及通式（I）的取代的芳基磺酰基氨基甲基膦酸衍生物，其中R，X，Y和Z如权利要求1所定义，其互变异构体，对映异构体，非对映异构体，混合物及其盐具有有价值的药理学性质，特别是 抑制糖原磷酸化酶a与糖原相关蛋白磷酸酶1（PP1）的GL亚基的相互作用，以及它们作为药物组合物的用途。
-
6.发明授权FURO[3,4-C]QUINOLINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION 有权FURO [3,4-C]喹啉衍生物，含有这些化合物的药物，它们的用途和制备方法
公开(公告)号：EP2760868B1
公开(公告)日：2018-04-25
申请号：EP12746369.3
申请日：2012-08-16
IPC分类号： C07D491/20 , A61K31/4355 , A61P9/00
CPC分类号： C07D491/20 , A61K31/4747 , A61K45/06
摘要： The present invention relates to compounds defined by formula I wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this protein.
-
公开(公告)号：EP3022210A1
公开(公告)日：2016-05-25
申请号：EP14738531.4
申请日：2014-07-14
IPC分类号： C07D519/00 , A61K31/437 , A61P3/00
CPC分类号： A61K31/437 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/541 , A61K45/06 , C07D493/04 , C07D519/00
摘要： The present invention relates to compounds of general formula I, wherein the group R1, R2, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
摘要翻译： 本发明涉及通式（I）的化合物，其中基团R 1，R 2，X和Y如权利要求1中所定义，其具有有价值的药理学性质，特别是与AMP-活化的蛋白激酶（AMPK ）并调节其活性。 该化合物适用于治疗和预防可受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
-
8.发明授权SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS 有权取代ARYLSULPHONYLGLYCINE，制备方法及其用途的药物组合物
公开(公告)号：EP2121600B1
公开(公告)日：2012-07-18
申请号：EP08709013.0
申请日：2008-02-15
发明人： WAGNER, Holger , LANGKOPF, Elke , STREICHER, Ruediger , ECKHARDT, Matthias , SCHULER-METZ, Annette , PAUTSCH, Alexander , SCHOELCH, Corinna
IPC分类号： C07D209/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , A61K31/404 , A61K31/416 , A61P3/10
CPC分类号： C07D209/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14
摘要： The present invention relates to substituted arylsulphonylglycines of general formula wherein R, R4, X, Y, Z and m are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen- associated protein phosphatase 1 (PP1 ), and their use as pharmaceutical compositions.
-
9.发明公开NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS 审中-公开新ARYLSULPHONYLGLYCINDERIVATE，生产及其作为药物
公开(公告)号：EP2279173A1
公开(公告)日：2011-02-02
申请号：EP09732153.3
申请日：2009-04-17
发明人： LANGKOPF, Elke , HIMMELSBACH, Frank , MACK, Juergen , PAUTSCH, Alexander , SCHOELCH, Corinna , SCHULER-METZ, Annette , STREICHER, Ruediger , WAGNER, Holger
IPC分类号： C07D213/40 , C07D213/74 , C07D215/40 , C07D239/26 , C07D271/06 , C07D271/10 , C07D307/52 , C07D295/15 , C07D295/108 , C07C311/21 , A61K31/47 , A61P3/10
CPC分类号： C07D271/06 , C07C311/21 , C07D213/40 , C07D213/74 , C07D215/40 , C07D239/26 , C07D271/10 , C07D295/108 , C07D295/15 , C07D307/52
摘要： The invention relates to substituted arylsulphonylglycine derivatives of general formula (I) wherein the groups R
a to R
f , A and Z are defined as in the specification and claims, which are suitable for preparing a pharmaceutical composition for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.-
10.发明公开ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS 审中-公开ARYLSULFONYLAMINOMETHYLPHOSPHONSÄUREDERIVATE，生产及其用途的药物组合物
公开(公告)号：EP2200987A1
公开(公告)日：2010-06-30
申请号：EP08803622.3
申请日：2008-09-04
发明人： LANGKOPF, Elke , PAUTSCH, Alexander , SCHOELCH, Corinna , SCHULER-METZ, Annette , STREICHER, Ruediger , WAGNER, Holger
IPC分类号： C07D215/38 , C07D217/22 , C07D219/08 , C07D237/28 , C07D239/72 , C07D471/04 , A61K31/4353 , A61K31/501 , A61P3/10
CPC分类号： C07D215/38 , C07D217/22 , C07D219/08 , C07D231/56 , C07D237/28 , C07D239/42 , C07D239/72 , C07D239/74 , C07D241/42 , C07D263/56 , C07D277/66 , C07D471/04
摘要： The invention relates tosubstitutedarylsulphonylaminomethylphosphonic acid derivativesof general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparinga medicament for the treatmentof metabolic disorders, particularlytype 1 or type 2 diabetesmellitus.
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.031 秒)
